These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37016946)

  • 1. Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
    Przybylski R; Abrams DJ
    Curr Opin Cardiol; 2023 Jul; 38(4):390-395. PubMed ID: 37016946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome.
    Roston TM; Wei J; Guo W; Li Y; Zhong X; Wang R; Estillore JP; Peltenburg PJ; Noguer FRI; Till J; Eckhardt LL; Orland KM; Hamilton R; LaPage MJ; Krahn AD; Tadros R; Vinocur JM; Kallas D; Franciosi S; Roberts JD; Wilde AAM; Jensen HK; Sanatani S; Chen SRW
    JAMA Cardiol; 2022 Jan; 7(1):84-92. PubMed ID: 34730774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H; Knollmann BC
    J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse Phenotypic Manifestations in a Family with a Novel RYR2 E4107A Variant.
    Hasegawa H; Tamura S; Nakajima T; Kawabata-Iwakawa R; Kobari T; Matsumoto N; Sano Y; Nishiyama M; Kurabayashi M; Kaneko Y; Nakatani Y; Ishii H
    Int Heart J; 2024; 65(3):580-585. PubMed ID: 38825499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Davidson R; Medeiros M
    J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
    Bergeman AT; Wilde AAM; van der Werf C
    Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A; Davis AM
    Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
    Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium Release Deficiency Syndrome: A New Inherited Arrhythmia Syndrome.
    Kallas D; Roberts JD; Sanatani S; Roston TM
    Card Electrophysiol Clin; 2023 Sep; 15(3):319-329. PubMed ID: 37558302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
    Mazzanti A; Kukavica D; Trancuccio A; Memmi M; Bloise R; Gambelli P; Marino M; Ortíz-Genga M; Morini M; Monteforte N; Giordano U; Keegan R; Tomasi L; Anastasakis A; Davis AM; Shimizu W; Blom NA; Santiago DJ; Napolitano C; Monserrat L; Priori SG
    JAMA Cardiol; 2022 May; 7(5):504-512. PubMed ID: 35353122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death.
    Zhong X; Guo W; Wei J; Tang Y; Liu Y; Zhang JZ; Tan VH; Zhang L; Wang R; Jones PP; Napolitano C; Priori SG; Chen SRW
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
    Roston TM; Van Petegem F; Sanatani S
    Curr Opin Cardiol; 2017 Jan; 32(1):78-85. PubMed ID: 27861184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
    Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
    J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.